Compounds > 5-chloropyrazinamide
Page last updated: 2024-11-08

5-chloropyrazinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID181450
CHEMBL ID222382
SCHEMBL ID1432968
MeSH IDM0287773

Synonyms (31)

Synonym
EN300-36256
5-chloropyrazinamide
5-chloro-pza
5-cl pza
5-chloropyrazine-2-carboxamide
21279-64-1
5cl-pza
CHEMBL222382
5-chloro-pyrazinamide
e2tjl7ur5a ,
2-carboxamido-5-chloropyrazine
unii-e2tjl7ur5a
5-chloro-2-pyrazinecarboxamide
pyrazinecarboxamide, 5-chloro-
AKOS009254414
FT-0647007
AM20070325
GFEFMHWOSWUJSO-UHFFFAOYSA-N
SY021612
mfcd10686873
SCHEMBL1432968
5-cl-pza
bdbm228816
DTXSID1040950
GS-5798
CS-W003733
BCP22046
Z362781434
SB17940
2-pyrazinecarboxamide, 5-chloro-
A847837
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)33.20000.00020.552110.0000AID1664156
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)33.20000.00120.48289.0000AID1664156
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (49)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
base-excision repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
double-strand break repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatin remodelingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
determination of adult lifespanNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
response to UVNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
retrotransposon silencingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of double-strand break repair via homologous recombinationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of lipid metabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
pericentric heterochromatin formationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of insulin secretionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of telomere maintenanceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IINAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
ketone biosynthetic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of protein import into nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
glucose homeostasisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of circadian rhythmNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of gene expression, epigeneticNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of glycolytic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of glucose importNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of protein export from nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of fibroblast proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of protein secretionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of lipid catabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein delipidationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
cardiac muscle cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of cold-induced thermogenesisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of protein localization to chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of protein localization to chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell population maintenanceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of chondrocyte proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of protein localization to plasma membraneNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of blood vessel branchingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein localization to site of double-strand breakNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
chromatin bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
damaged DNA bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleotidyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatin DNA bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleosome bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein homodimerization activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K18 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+-protein-arginine ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
DNA damage sensor activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K56 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+- protein-lysine ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
TORC2 complex bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
nucleolusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
pericentric heterochromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
endoplasmic reticulumNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
site of double-strand breakNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
site of DNA damageNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
intracellular membrane-bounded organelleNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromosome, subtelomeric regionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (82)

Assay IDTitleYearJournalArticle
AID584540Activity of PzaA in Mycobacterium smegmatis mc27035 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584367Inhibition of Fatty acid synthase type 1 in Mycobacterium smegmatis mc27031 at 1500 ug/ml after 2 hrs by HPLC2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584543Activity of PzaA in Mycobacterium smegmatis mc27038 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064507Antibacterial activity against Staphylococcus epidermidis H 6966/08 after 48 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064503Antifungal activity against Candida krusei E28 after 72 to 120 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID279003Inhibition of fatty acid synthase 1 in Mycobacterium tuberculosis assessed as incorporation of [1-14C]acetate in C16 biosynthesis at 250 ug/ml2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
AID1064510Antibacterial activity against Enterococcus sp. J 14365/08 after 24 to 48 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584542Activity of PzaA in Mycobacterium smegmatis mc27037 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID406202Inhibition of Mycobacterium tuberculosis fatty acid synthase 1 expressed in Mycobacterium smegmatis mc2 2700 assessed as NADPH oxidation using variable concentration of NADPH by spectrophotometry2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
AID584535Activity of PzaA in Mycobacterium smegmatis mc2155 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064519Cytotoxicity against human HepG2 cells after 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064520Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium tuberculosis H37Rv CNCTC My 331/882014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584368Inhibition of Fatty acid synthase type 1 in Mycobacterium smegmatis mc2155 at 250 ug/ml after 2 hrs by HPLC2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584348Antimicrobial activity against Mycobacterium smegmatis mc27032 harboring deltaMSMEG_1088 from Mycobacterium smegmatis mc2155 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584538Activity of PzaA in Mycobacterium smegmatis mc27032 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID406066Inhibition of Mycobacterium tuberculosis fatty acid synthase 1 expressed in Mycobacterium smegmatis mc2 2700 assessed as NADPH oxidation at 100 uM of NADPH by spectrophotometry2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
AID584536Activity of PzaA in Mycobacterium smegmatis mc22612 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584533Activity of PzaA in Mycobacterium smegmatis mc27091 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064517Antimycobacterial activity against pyrazinamide-resistant Mycobacterium fortuitum2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584353Antimicrobial activity against Mycobacterium smegmatis mc27038 harboring attBL5::Ptc::pzaAMsmeg from Mycobacterium smegmatis mc2155 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID754908Antimycobacterial activity against pyrazinamide-resistant Mycobacterium fortuitum ATCC 49601 assessed as growth inhibition after 24 hrs to 2 weeks by microbroth dilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.
AID584357Antimicrobial activity against Mycobacterium smegmatis mc27092 harboring Mycobacterium tuberculosis H37Ra attBL5:::Ptc::pzaAMsmeg after 11 days by broth microdilution method at pH 6.82010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064526Antimycobacterial activity against pyrazinamide-resistant Mycobacterium avium2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID754911Antimycobacterial activity against pyrazinamide-resistant Mycobacterium fortuitum ATCC 49403 assessed as growth inhibition after 24 hrs to 2 weeks by microbroth dilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.
AID1064504Antifungal activity against Candida tropicalis 156 after 72 to 120 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064511Antibacterial activity against methicillin-resistant Staphylococcus epidermidis H 5996/08 after 24 to 48 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584354Antimicrobial activity against Mycobacterium tuberculosis H37Ra after 11 days by broth microdilution method at pH 62010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584530Activity of PzaA in Mycobacterium smegmatis mc27092 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064498Antifungal activity against Trichophyton mentagrophytes 445 after 72 to 120 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064512Antibacterial activity against Pseudomonas aeruginosa CCM 1961 after 24 to 48 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584360Antimicrobial activity against Mycobacterium bovis BCG Pasteur after 11 days by broth microdilution method at pH 62010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064525Antimycobacterial activity against Mycobacterium tuberculosis H37Rv CNCTC My 331/88 after 5 days by microplate alamar blue assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID754913Antimycobacterial activity against pyrazinamide-susceptible Mycobacterium tuberculosis ATCC 35801 assessed as growth inhibition after 24 hrs to 2 weeks by microbroth dilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.
AID584363Antimicrobial activity against Mycobacterium smegmatis mc27091 harboring Mycobacterium bovis BCG Pasteur attBL5:::Ptc::pzaAMsmeg after 48 hrs by broth microdilution method at pH 6.82010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584537Activity of PzaA in Mycobacterium smegmatis mc27031 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584541Activity of PzaA in Mycobacterium smegmatis mc27036 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584529Activity of PncA in Mycobacterium tuberculosis H37Ra assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID754914Antimycobacterial activity against pyrazinamide-susceptible Mycobacterium tuberculosis ATCC 27294 assessed as growth inhibition after 24 hrs to 2 weeks by microbroth dilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.
AID1064513Antibacterial activity against Escherichia coli CCM 4517 after 24 to 48 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584351Antimicrobial activity against Mycobacterium smegmatis mc27036 harboring deltaMSMEG_1090 from Mycobacterium smegmatis mc22612 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584539Activity of PzaA in Mycobacterium smegmatis mc27034 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064500Antifungal activity against Aspergillus fumigatus 231 after 72 to 120 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064524Antimycobacterial activity against pyrazinamide-resistant Mycobacterium kansasii CNCTC My 235/80 after 5 days by microplate alamar blue assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584355Antimicrobial activity against Mycobacterium tuberculosis H37Ra after 11 days by broth microdilution method at pH 6.82010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584350Antimicrobial activity against Mycobacterium smegmatis mc27035 harboring deltaMSMEG_1090 from Mycobacterium smegmatis mc2155 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584532Activity of pyrazinamidase in Mycobacterium bovis BCG Pasteur assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064514Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 24 to 48 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584345Antimicrobial activity against Mycobacterium smegmatis mc2155 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064505Antifungal activity against Candida albicans ATCC 44859 after 72 to 120 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064509Antibacterial activity against Klebsiella pneumoniae D 11750/08 after 24 to 48 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584358Antimicrobial activity against Mycobacterium smegmatis mc27093 harboring Mycobacterium tuberculosis H37Ra attBL5:::Ptc::pzaA from Mycobacterium tuberculosis after 11 days by broth microdilution method at pH 62010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064523Antimycobacterial activity against pyrazinamide-resistant Mycobacterium avium CNCTC My 80/72 after 5 days by microplate alamar blue assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064508Antibacterial activity against ESBL positive Klebsiella pneumoniae J 14368/08 after 24 to 48 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID754910Antimycobacterial activity against pyrazinamide-resistant Mycobacterium bovis ATCC 27289 assessed as growth inhibition after 24 hrs to 2 weeks by microbroth dilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.
AID1064506Antifungal activity against Trichophyton mentagrophytes after 72 to 120 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064521Lipophilicity, log K of the compound by HPLC analysis2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584531Activity of PzaA in Mycobacterium smegmatis mc27093 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584364Antimicrobial activity against Mycobacterium smegmatis mc27099 harboring Mycobacterium bovis BCG Pasteur attBL5:::Ptc::pzaAMsmeg after 48 hrs by broth microdilution method at pH 62010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584347Antimicrobial activity against Mycobacterium smegmatis mc27031 harboring MSMEG_1088::magellan4 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584361Antimicrobial activity against Mycobacterium bovis BCG Pasteur after 11 days by broth microdilution method at pH 6.82010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064527Antimycobacterial activity against pyrazinamide-resistant Mycobacterium smegmatis2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064499Antifungal activity against Absidia corymbifera 272 after 72 to 120 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584365Antimicrobial activity against Mycobacterium smegmatis mc27099 harboring Mycobacterium bovis BCG Pasteur attBL5:::Ptc::pzaAMsmeg after 48 hrs by broth microdilution method at pH 6.82010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064501Antifungal activity against Candida glabrata 20/I after 72 to 120 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1664156Inhibition of His-tagged human SIRT6 expressed in Escherichia coli BL21(DE3) using Ac-p53 as substrate by fluorescence-based coupled-enzyme assay2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors.
AID1064502Antifungal activity against Trichosporon asahii 1188 after 72 to 120 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584356Antimicrobial activity against Mycobacterium smegmatis mc27092 harboring Mycobacterium tuberculosis H37Ra attBL5:::Ptc::pzaAMsmeg after 48 hrs by broth microdilution method at pH 62010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID1064515Antibacterial activity against Staphylococcus epidermidis H 6966/08 up to 500 uM after 24 to 48 hrs by microdilution broth method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID584359Antimicrobial activity against Mycobacterium smegmatis mc27093 harboring Mycobacterium tuberculosis H37Ra attBL5:::Ptc::pzaA from Mycobacterium tuberculosis after 11 days by broth microdilution method at pH 6.82010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID406065Inhibition of Mycobacterium tuberculosis fatty acid synthase 1 expressed in Mycobacterium smegmatis mc2 2700 assessed as NADPH oxidation by spectrophotometry2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
AID754909Antimycobacterial activity against pyrazinamide-resistant Mycobacterium bovis ATCC 35720 assessed as growth inhibition after 24 hrs to 2 weeks by microbroth dilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.
AID584534Activity of PzaA in Mycobacterium smegmatis mc27099 assessed as compound turnover per ml of microbial cells after 30 mins by calorimetric analysis2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584352Antimicrobial activity against 5-Cl-PZA-resistant Mycobacterium smegmatis mc27037 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID754912Antimycobacterial activity against pyrazinamide-resistant Mycobacterium kansasii assessed as growth inhibition after 24 hrs to 2 weeks by microbroth dilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.
AID584349Antimicrobial activity against Mycobacterium smegmatis mc27034 harboring deltaMSMEG_1090 from Mycobacterium smegmatis mc27031 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584362Antimicrobial activity against Mycobacterium smegmatis mc27091 harboring Mycobacterium bovis BCG Pasteur attBL5:::Ptc::pzaAMsmeg after 48 hrs by broth microdilution method at pH 62010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID584346Antimicrobial activity against 5-Cl PZA-resistant Mycobacterium smegmatis mc22612after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID406203Inhibition of Mycobacterium tuberculosis fatty acid synthase 1 expressed in Mycobacterium smegmatis mc2 2700 assessed as [2-14C]]malonyl-CoA incorporation into fatty acid at 3000 uM2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
AID1064518Antimycobacterial activity against pyrazinamide-resistant Mycobacterium kansasii2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064528Antimycobacterial activity against pyrazinamide-sensitive Mycobacterium tuberculosis2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1064516Antimycobacterial activity against pyrazinamide-resistant Mycobacterium avium CNCTC My 152/73 after 5 days by microplate alamar blue assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
AID1802837Fluorimetric Assay from Article 10.1002/cbic.201600655: \\Studies of the Binding of Modest Modulators of the Human Enzyme, Sirtuin 6, by STD NMR.\\2017Chembiochem : a European journal of chemical biology, 05-18, Volume: 18, Issue:10
Studies of the Binding of Modest Modulators of the Human Enzyme, Sirtuin 6, by STD NMR.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's5 (35.71)29.6817
2010's7 (50.00)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.10 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
beta-alanine
[no description available]		2.110amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		2.5220pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
pyrazinamide
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.		3.99130monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
pyrazinoic acid
pyrazinoic acid: active metabolite of pyrazinamide; structure. pyrazine-2-carboxylic acid : The parent compound of the class of pyrazinecarboxylic acids, that is pyrazine bearing a single carboxy substituent. The active metabolite of the antitubercular drug pyrazinamide.		3.4370pyrazinecarboxylic acidantitubercular agent;
drug metabolite
benzamide
benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.		2.0310benzamides
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.110aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.0810conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.7630carbohydrazideantitubercular agent;
drug allergen
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		2.110penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
pantothenic acid
Pantothenic Acid: A butyryl-beta-alanine that can also be viewed as pantoic acid complexed with BETA ALANINE. It is incorporated into COENZYME A and protects cells against peroxidative damage by increasing the level of GLUTATHIONE.. pantothenic acid : A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.. vitamin B5 : Any member of a group of vitamers that belong to the chemical structural class called pantothenic acids that exhibit biological activity against vitamin B5 deficiency. Deficiency of vitamin B5 is rare due to its widespread distribution in whole grain cereals, legumes and meat. Symptoms associated with vitamin B5 deficiency are difficult to asses since they are subtle and resemble those of other B vitamin deficiencies. The vitamers include (R)-pantothenic acid and its ionized and salt forms.. (R)-pantothenate : A pantothenate that is the conjugate base of (R)-pantothenic acid, obtained by deprotonation of the carboxy group.. (R)-pantothenic acid : A pantothenic acid having R-configuration.		2.110pantothenic acid;
vitamin B5		antidote to curare poisoning;
geroprotector;
human blood serum metabolite
framycetin
Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.		2.110aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		2.0310ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
propyl pyrazinoate
[no description available]		2.7430
1-(4-nitrophenyl)piperazine
1-(4-nitrophenyl)piperazine: structure in first source		2.2510
pantetheine
Pantetheine: An intermediate in the pathway of coenzyme A formation in mammalian liver and some microorganisms.. pantetheine : An amide obtained by formal condensation of the carboxy group of pantothenic acid and the amino group of cysteamine.		2.110pantetheines;
thiol		human metabolite;
metabolite;
mouse metabolite
cerulenin
Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.		2.0310epoxide;
monocarboxylic acid amide		antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Koch's Disease
[description not available]		02.4620
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		07.4620
Pulmonary Consumption
[description not available]		0210
Tuberculosis, Pulmonary
MYCOBACTERIUM infections of the lung.		0210